LUPIN-PROPRANOLOL LA CAPSULE (EXTENDED RELEASE)

国: カナダ

言語: 英語

ソース: Health Canada

有効成分:

PROPRANOLOL HYDROCHLORIDE

から入手可能:

LUPIN PHARMA CANADA LIMITED

ATCコード:

C07AA05

INN（国際名）:

PROPRANOLOL

投薬量:

160MG

医薬品形態:

CAPSULE (EXTENDED RELEASE)

構図:

PROPRANOLOL HYDROCHLORIDE 160MG

投与経路:

ORAL

パッケージ内のユニット:

15G/50G

処方タイプ:

Prescription

治療領域:

BETA-ADRENERGIC BLOCKING AGENTS

製品概要:

Active ingredient group (AIG) number: 0101831006; AHFS:

認証ステータス:

APPROVED

承認日:

2019-08-30

製品の特徴

_Page 1 of 30 _
PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION
PR
LUPIN-PROPRANOLOL LA
Propranolol Hydrochloride Extended-Release Capsules
Extended-Release Capsules, 60 mg, 80 mg, 120 mg and 160 mg, Oral
USP
Beta-Adrenergic Receptor Blocking Agent
Lupin Pharma Canada Ltd.
1001 De Maisonneuve Est, Suite 304
Montréal, Quebec
H2L 4P9
Date of Initial Authorization:
AUG 28, 2019
Date of Revision:
JAN 14, 2022
Submission Control Number: 255723
_Page 2 of 30 _
RECENT MAJOR LABEL CHANGES
TABLE OF CONTENTS
SECTIONS OR SUBSECTIONS THAT ARE NOT APPLICABLE AT THE TIME OF
AUTHORIZATION ARE NOT
LISTED.
RECENT MAJOR LABEL CHANGES
.....................................................................................
2
TABLE OF CONTENTS
..........................................................................................................
2
PART I: HEALTH PROFESSIONAL
INFORMATION...............................................................
4
1
INDICATIONS...............................................................................................................
4
1.1
PEDIATRICS
.............................................................................................................
4
1.2
GERIATRICS
..............................................................................................................
4
2
CONTRAINDICATIONS
................................................................................................
4
4
DOSAGE AND ADMINISTRATION
...............................................................................
5
4.1
DOSING CONSIDERATIONS
........................................................................................
5
4.2
RECOMMENDED DOSE AND DOSAGE ADJUSTMENT
.................................................... 5
4.4
ADMINISTRATION
......................................................................................................
6
4.5
MISSED DOSE
.........................................................................................................
6
5
OVERDOSAGE
.....